{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:13:57Z","timestamp":1783401237379,"version":"3.54.6"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04986-2","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:55:17Z","timestamp":1778666117000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential diagnostic, prognostic, and therapeutic implications of ferroptosis in myelodysplastic syndromes"],"prefix":"10.1007","volume":"17","author":[{"given":"Muluken","family":"Walle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fasil","family":"Getu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bisrat Birke","family":"Teketelew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Chane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getaneh","family":"Mola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dereje Mengesha","family":"Berta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"14","key":"4986_CR1","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1056\/NEJMra1904794","volume":"383","author":"M Cazzola","year":"2020","unstructured":"Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383(14):1358\u201374.","journal-title":"N Engl J Med"},{"key":"4986_CR2","doi-asserted-by":"publisher","first-page":"100791","DOI":"10.1016\/j.blre.2020.100791","volume":"48","author":"C Saygin","year":"2021","unstructured":"Saygin C, Carraway HE. Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021;48:100791.","journal-title":"Blood Rev"},{"key":"4986_CR3","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3389\/fonc.2020.01656","volume":"10","author":"Q Lv","year":"2020","unstructured":"Lv Q, Niu H, Yue L, Liu J, Yang L, Liu C, et al. Abnormal ferroptosis in myelodysplastic syndrome. Front Oncol. 2020;10:1656.","journal-title":"Front Oncol"},{"issue":"12","key":"4986_CR4","first-page":"2454","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood J Am Soc Hematol. 2012;120(12):2454\u201365.","journal-title":"Blood J Am Soc Hematol"},{"issue":"8","key":"4986_CR5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s10147-019-01462-6","volume":"24","author":"N Hosono","year":"2019","unstructured":"Hosono N. Genetic abnormalities and pathophysiology of MDS. Int J Clin Oncol. 2019;24(8):885\u201392.","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"4986_CR6","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1200\/JCO.2010.31.1175","volume":"29","author":"R Bejar","year":"2011","unstructured":"Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011;29(5):504\u201315.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4986_CR7","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","volume":"30","author":"J Schanz","year":"2012","unstructured":"Schanz J, T\u00fcchler H, Sol\u00e9 F, Mallo M, Luno E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820\u20139.","journal-title":"J Clin Oncol"},{"key":"4986_CR8","doi-asserted-by":"crossref","unstructured":"Hasserjian RP, Germing U, Malcovati L. Diagnosis and classification of myelodysplastic syndromes. Blood. 2023.","DOI":"10.1182\/blood.2023020078"},{"issue":"2","key":"4986_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","volume":"31","author":"D Tang","year":"2021","unstructured":"Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31(2):107\u201325.","journal-title":"Cell Res"},{"issue":"4","key":"4986_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"4986_CR11","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1080\/15548627.2020.1810918","volume":"17","author":"X Chen","year":"2021","unstructured":"Chen X, Li J, Kang R, Klionsky DJ, Tang D. Ferroptosis: machinery and regulation. Autophagy. 2021;17(9):2054\u201381.","journal-title":"Autophagy"},{"issue":"1","key":"4986_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41420-024-02037-9","volume":"10","author":"S Wang","year":"2024","unstructured":"Wang S, Guo Q, Zhou L, Xia X. Ferroptosis: A double-edged sword. Cell Death Discovery. 2024;10(1):265.","journal-title":"Cell Death Discovery"},{"issue":"2","key":"4986_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Angeli JPF, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273\u201385.","journal-title":"Cell"},{"issue":"12","key":"4986_CR14","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/iub.2897","volume":"76","author":"A Papadimitriou-Tsantarliotou","year":"2024","unstructured":"Papadimitriou-Tsantarliotou A, Avgeros C, Konstantinidou M, Vizirianakis IS. Analyzing the role of ferroptosis in ribosome\u2010related bone marrow failure disorders: From pathophysiology to potential pharmacological exploitation. IUBMB Life. 2024;76(12):1011\u201334.","journal-title":"IUBMB Life"},{"key":"4986_CR15","doi-asserted-by":"publisher","first-page":"627662","DOI":"10.3389\/fimmu.2020.627662","volume":"11","author":"S Weber","year":"2021","unstructured":"Weber S, Parmon A, Kurrle N, Schn\u00fctgen F, Serve H. The clinical significance of iron overload and iron metabolism in myelodysplastic syndrome and acute myeloid leukemia. Front Immunol. 2021;11:627662.","journal-title":"Front Immunol"},{"issue":"1","key":"4986_CR16","first-page":"360438","volume":"2014","author":"A Ayala","year":"2014","unstructured":"Ayala A, Mu\u00f1oz MF, Arg\u00fcelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy\u20102\u2010nonenal. Oxidative Med Cell Longev. 2014;2014(1):360438.","journal-title":"Oxidative Med Cell Longev"},{"key":"4986_CR17","doi-asserted-by":"publisher","first-page":"101328","DOI":"10.1016\/j.redox.2019.101328","volume":"28","author":"G Miotto","year":"2020","unstructured":"Miotto G, Rossetto M, Di Paolo ML, Orian L, Venerando R, Roveri A, et al. Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol. 2020;28:101328.","journal-title":"Redox Biol"},{"issue":"5","key":"4986_CR18","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060\u201372.","journal-title":"Cell"},{"issue":"7","key":"4986_CR19","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/ijc.28159","volume":"133","author":"C Louandre","year":"2013","unstructured":"Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Mazi\u00e8re JC, Chauffert B, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer. 2013;133(7):1732\u201342.","journal-title":"Int J Cancer"},{"key":"4986_CR20","doi-asserted-by":"publisher","first-page":"866325","DOI":"10.3389\/fphar.2022.866325","volume":"13","author":"Z Cui","year":"2022","unstructured":"Cui Z, Fu Y, Yang Z, Gao Z, Feng H, Zhou M, et al. Comprehensive analysis of a ferroptosis pattern and associated prognostic signature in acute myeloid leukemia. Front Pharmacol. 2022;13:866325.","journal-title":"Front Pharmacol"},{"issue":"3","key":"4986_CR21","doi-asserted-by":"publisher","first-page":"188890","DOI":"10.1016\/j.bbcan.2023.188890","volume":"1878","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wan Y, Jiang Y, Zhang L, Cheng W. GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment. Biochim et Biophys Acta (BBA)-Reviews Cancer. 2023;1878(3):188890.","journal-title":"Biochim et Biophys Acta (BBA)-Reviews Cancer"},{"issue":"18","key":"4986_CR22","doi-asserted-by":"publisher","first-page":"1800311","DOI":"10.1002\/pmic.201800311","volume":"19","author":"GC Forcina","year":"2019","unstructured":"Forcina GC, Dixon SJ. GPX4 at the crossroads of lipid homeostasis and ferroptosis. Proteomics. 2019;19(18):1800311.","journal-title":"Proteomics"},{"issue":"1","key":"4986_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91\u20138.","journal-title":"Nat Chem Biol"},{"issue":"5","key":"4986_CR24","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1016\/j.bbagen.2012.09.008","volume":"1830","author":"SC Lu","year":"2013","unstructured":"Lu SC. Glutathione synthesis. Biochim et Biophys Acta (BBA)-General Subj. 2013;1830(5):3143\u201353.","journal-title":"Biochim et Biophys Acta (BBA)-General Subj"},{"issue":"8","key":"4986_CR25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12(8):599\u2013620.","journal-title":"Protein Cell"},{"issue":"12","key":"4986_CR26","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/ncb3064","volume":"16","author":"JP Friedmann Angeli","year":"2014","unstructured":"Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16(12):1180\u201391.","journal-title":"Nat Cell Biol"},{"issue":"11","key":"4986_CR27","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00018-016-2194-1","volume":"73","author":"JY Cao","year":"2016","unstructured":"Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci. 2016;73(11):2195\u2013209.","journal-title":"Cell Mol Life Sci"},{"key":"4986_CR28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.bbrc.2020.10.083","volume":"534","author":"Y Li","year":"2021","unstructured":"Li Y, Xia J, Shao F, Zhou Y, Yu J, Wu H, et al. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis. Biochem Biophys Res Commun. 2021;534:877\u201384.","journal-title":"Biochem Biophys Res Commun"},{"key":"4986_CR29","doi-asserted-by":"publisher","first-page":"116727","DOI":"10.1016\/j.biopha.2024.116727","volume":"175","author":"Y Gao","year":"2024","unstructured":"Gao Y, Jin F, Zhang P, Zheng C, Zheng X, Xie J, et al. Elesclomol-copper synergizes with imidazole ketone erastin by promoting cuproptosis and ferroptosis in myelodysplastic syndromes. Biomed Pharmacother. 2024;175:116727.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"4986_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/0378-1119(94)90400-6","volume":"144","author":"RS Esworthy","year":"1994","unstructured":"Esworthy RS, Doan K, Doroshow JH, Chu F-F. Cloning and sequencing of the cDNA encoding a human testis phospholipid hydroperoxide glutathione peroxidase. Gene. 1994;144(2):317\u20138.","journal-title":"Gene"},{"issue":"3","key":"4986_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/carcin\/bgad094","volume":"45","author":"Y Hori","year":"2024","unstructured":"Hori Y, Yoh T, Nishino H, Okura K, Kurimoto M, Takamatsu Y, et al. Ferroptosis-related gene glutathione peroxidase 4 promotes reprogramming of glucose metabolism via Akt\u2013mTOR axis in intrahepatic cholangiocarcinoma. Carcinogenesis. 2024;45(3):119\u201330.","journal-title":"Carcinogenesis"},{"issue":"11","key":"4986_CR32","first-page":"5508","volume":"11","author":"L Luo","year":"2021","unstructured":"Luo L, Wang H, Tian W, Zeng J, Huang Y, Luo H. Targeting ferroptosis for cancer therapy: iron metabolism and anticancer immunity. Am J Cancer Res. 2021;11(11):5508.","journal-title":"Am J Cancer Res"},{"key":"4986_CR33","doi-asserted-by":"crossref","unstructured":"Liang D, Jiang X. Redundant or resilient? A systems view of ferroptosis surveillance mechanisms. Cell Chem Biology. 2026.","DOI":"10.1016\/j.chembiol.2025.11.013"},{"key":"4986_CR34","doi-asserted-by":"publisher","first-page":"1330910","DOI":"10.3389\/fphar.2023.1330910","volume":"14","author":"X Zhao","year":"2024","unstructured":"Zhao X, Li X, Xu Y. Ferroptosis: a dual-edged sword in tumour growth. Front Pharmacol. 2024;14:1330910.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4986_CR35","first-page":"8855038","volume":"2020","author":"L Huang","year":"2020","unstructured":"Huang L, Liu Z, Liu H, Ding K, Mi F, Xiang C, et al. Iron Overload Impairs Bone Marrow Mesenchymal Stromal Cells from Higher-Risk MDS Patients by Regulating the ROS\u2010Related Wnt\/\u03b2\u2010Catenin Pathway. Stem Cells Int. 2020;2020(1):8855038.","journal-title":"Stem Cells Int"},{"issue":"10","key":"4986_CR36","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.3390\/ijms22105202","volume":"22","author":"V Petzer","year":"2021","unstructured":"Petzer V, Theurl I, Weiss G, Wolf D. Environmental aspects in myelodysplastic syndrome. Int J Mol Sci. 2021;22(10):5202.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4986_CR37","first-page":"873","volume":"124","author":"N Shenoy","year":"2014","unstructured":"Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood J Am Soc Hematol. 2014;124(6):873\u201381.","journal-title":"Blood J Am Soc Hematol"},{"key":"4986_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.leukres.2017.10.001","volume":"62","author":"E Angelucci","year":"2017","unstructured":"Angelucci E, Cianciulli P, Finelli C, Mecucci C, Voso MT, Tura S. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes. Leuk Res. 2017;62:108\u201315.","journal-title":"Leuk Res"},{"issue":"5","key":"4986_CR39","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.leukres.2014.01.016","volume":"38","author":"R Cui","year":"2014","unstructured":"Cui R, Gale RP, Zhu G, Xu Z, Qin T, Zhang Y, et al. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. Leuk Res. 2014;38(5):545\u201350.","journal-title":"Leuk Res"},{"issue":"1","key":"4986_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-010-1091-1","volume":"90","author":"N Gattermann","year":"2011","unstructured":"Gattermann N, Rachmilewitz EA. Iron overload in MDS\u2014pathophysiology, diagnosis, and complications. Ann Hematol. 2011;90(1):1\u201310.","journal-title":"Ann Hematol"},{"issue":"4","key":"4986_CR41","first-page":"392","volume":"9","author":"L Lyle","year":"2018","unstructured":"Lyle L, Hirose A. Iron overload in myelodysplastic syndromes: pathophysiology, consequences, diagnosis, and treatment. J Adv practitioner Oncol. 2018;9(4):392.","journal-title":"J Adv practitioner Oncol"},{"key":"4986_CR42","doi-asserted-by":"publisher","first-page":"1469178","DOI":"10.3389\/fonc.2024.1469178","volume":"14","author":"X Gou","year":"2024","unstructured":"Gou X, Tang X, Liu C, Chen Z. Ferroptosis: a new mechanism of traditional Chinese medicine for treating hematologic malignancies. Front Oncol. 2024;14:1469178.","journal-title":"Front Oncol"},{"issue":"11","key":"4986_CR43","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1089\/ars.2014.5941","volume":"21","author":"A Ludin","year":"2014","unstructured":"Ludin A, Gur-Cohen S, Golan K, Kaufmann KB, Itkin T, Medaglia C, et al. Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment. Antioxid Redox Signal. 2014;21(11):1605\u201319.","journal-title":"Antioxid Redox Signal"},{"issue":"10","key":"4986_CR44","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.3324\/haematol.2018.193128","volume":"103","author":"X Jin","year":"2018","unstructured":"Jin X, He X, Cao X, Xu P, Xing Y, Sui S, et al. Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice. Haematologica. 2018;103(10):1627.","journal-title":"Haematologica"},{"issue":"8","key":"4986_CR45","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1111\/jcmm.14511","volume":"23","author":"T Xu","year":"2019","unstructured":"Xu T, Ding W, Ji X, Ao X, Liu Y, Yu W, et al. Molecular mechanisms of ferroptosis and its role in cancer therapy. J Cell Mol Med. 2019;23(8):4900\u201312.","journal-title":"J Cell Mol Med"},{"key":"4986_CR46","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1182\/blood-2023-185703","volume":"142","author":"J Legrand","year":"2023","unstructured":"Legrand J, Ouled-Haddou H, Djordjevic S, Bouzidi T, Gomila C, Garcon L, et al. Downregulation of SLC7A11 in MDS-SF3B1 Patients Induces a High Sensitivity of Erythroid Precursors to Ferroptosis. Blood. 2023;142:4585.","journal-title":"Blood"},{"issue":"15","key":"4986_CR47","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","volume":"365","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384\u201395.","journal-title":"N Engl J Med"},{"issue":"2","key":"4986_CR48","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241\u20137.","journal-title":"Leukemia"},{"key":"4986_CR49","doi-asserted-by":"publisher","first-page":"1116438","DOI":"10.3389\/fonc.2023.1116438","volume":"13","author":"M Jiang","year":"2023","unstructured":"Jiang M, Chen M, Liu Q, Jin Z, Yang X, Zhang W. SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process. Front Oncol. 2023;13:1116438.","journal-title":"Front Oncol"},{"issue":"5","key":"4986_CR50","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s12185-012-1048-3","volume":"95","author":"S Kikuchi","year":"2012","unstructured":"Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, et al. Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome. Int J Hematol. 2012;95(5):527\u201334.","journal-title":"Int J Hematol"},{"issue":"1","key":"4986_CR51","doi-asserted-by":"publisher","first-page":"2288475","DOI":"10.1080\/16078454.2023.2288475","volume":"28","author":"X Chen","year":"2023","unstructured":"Chen X, Li C, Wang Y, Geng S, Xiao M, Zeng L, et al. Diagnostic and prognostic value of ferroptosis-related genes in patients with Myelodysplastic neoplasms. Hematology. 2023;28(1):2288475.","journal-title":"Hematology"},{"issue":"4","key":"4986_CR52","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1002\/iid3.1221","volume":"12","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, He J, Wei R, Liu J. Construction and experimental validation of a novel ferroptosis-related gene signature for myelodysplastic syndromes. Immun Inflamm Dis. 2024;12(4):e1221.","journal-title":"Immun Inflamm Dis"},{"issue":"7\u20138","key":"4986_CR53","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1101\/gad.334219.119","volume":"34","author":"D Venkatesh","year":"2020","unstructured":"Venkatesh D, O\u2019Brien NA, Zandkarimi F, Tong DR, Stokes ME, Dunn DE, et al. MDM2 and MDMX promote ferroptosis by PPAR\u03b1-mediated lipid remodeling. Genes Dev. 2020;34(7\u20138):526\u201343.","journal-title":"Genes Dev"},{"issue":"11","key":"4986_CR54","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","volume":"12","author":"NG Daver","year":"2022","unstructured":"Daver NG, Maiti A, Kadia TM, Vyas P, Majeti R, Wei AH, et al. TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions. Cancer Discov. 2022;12(11):2516\u201329.","journal-title":"Cancer Discov"},{"issue":"7545","key":"4986_CR55","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang L, Kon N, Li T, Wang S-J, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57\u201362.","journal-title":"Nature"},{"issue":"2","key":"4986_CR56","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/bjh.18608","volume":"201","author":"N Salomao","year":"2023","unstructured":"Salomao N, Maslah N, Giulianelli A, Drevon L, Aguinaga L, Gu X, et al. Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol. 2023;201(2):234\u201348.","journal-title":"Br J Haematol"},{"issue":"2","key":"4986_CR57","doi-asserted-by":"publisher","first-page":"106","DOI":"10.6004\/jnccn.2022.0009","volume":"20","author":"PL Greenberg","year":"2022","unstructured":"Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, et al. Myelodysplastic Syndromes, Version 3.2022: Featured Updates to the NCCN Guidelines. JNCCN J Natl Compr Cancer Netw. 2022;20(2):106\u201317.","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"issue":"1","key":"4986_CR58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-022-00402-5","volume":"8","author":"H Li","year":"2022","unstructured":"Li H, Hu F, Gale RP, Sekeres MA, Liang Y. Myelodysplastic syndromes. Nat reviews Disease primers. 2022;8(1):74.","journal-title":"Nat reviews Disease primers"},{"issue":"43","key":"4986_CR59","doi-asserted-by":"publisher","first-page":"73483","DOI":"10.18632\/oncotarget.19008","volume":"8","author":"P Valent","year":"2017","unstructured":"Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017;8(43):73483.","journal-title":"Oncotarget"},{"issue":"17","key":"4986_CR60","first-page":"4690","volume":"118","author":"K Naqvi","year":"2011","unstructured":"Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, et al. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood J Am Soc Hematol. 2011;118(17):4690\u20133.","journal-title":"Blood J Am Soc Hematol"},{"key":"4986_CR61","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.critrevonc.2018.07.013","volume":"133","author":"Y Tang","year":"2019","unstructured":"Tang Y, Miao M, Han S, Qi J, Wang H, Ruan C, et al. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis. Crit Rev Oncol\/Hematol. 2019;133:74\u201383.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"2","key":"4986_CR62","first-page":"233","volume":"126","author":"L Malcovati","year":"2015","unstructured":"Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, J\u00e4dersten M, Jansson M, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood J Am Soc Hematol. 2015;126(2):233\u201341.","journal-title":"Blood J Am Soc Hematol"},{"issue":"7","key":"4986_CR63","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41419-024-06866-5","volume":"15","author":"L Liu","year":"2024","unstructured":"Liu L, Yang C, Zhu L, Wang Y, Zheng F, Liang L, et al. RSL3 enhances ROS-mediated cell apoptosis of myelodysplastic syndrome cells through MYB\/Bcl-2 signaling pathway. Cell Death Dis. 2024;15(7):465.","journal-title":"Cell Death Dis"},{"issue":"21","key":"4986_CR64","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.3390\/cancers13215392","volume":"13","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Gao S-J, Soubise B, Douet-Guilbert N, Liu Z-L, Troadec M-B. TP53 in myelodysplastic syndromes. Cancers. 2021;13(21):5392.","journal-title":"Cancers"},{"issue":"30","key":"4986_CR65","doi-asserted-by":"publisher","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","volume":"23","author":"L Malcovati","year":"2005","unstructured":"Malcovati L, Porta MGD, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594\u2013603.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4986_CR66","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3324\/haematol.2017.171884","volume":"103","author":"L de Swart","year":"2017","unstructured":"de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hellstr\u00f6m-Lindberg E, et al. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. Haematologica. 2017;103(1):69.","journal-title":"Haematologica"},{"issue":"3","key":"4986_CR67","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3324\/haematol.2009.011429","volume":"95","author":"EP Alessandrino","year":"2009","unstructured":"Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Angelucci E, Van Lint MT, et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica. 2009;95(3):476.","journal-title":"Haematologica"},{"issue":"2","key":"4986_CR68","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3324\/haematol.2022.280723","volume":"108","author":"J Teichman","year":"2022","unstructured":"Teichman J, Geddes M, Zhu N, Keating M-M, Sabloff M, Christou G, et al. High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes. Haematologica. 2022;108(2):532.","journal-title":"Haematologica"},{"key":"4986_CR69","doi-asserted-by":"publisher","first-page":"103367","DOI":"10.1016\/j.critrevonc.2021.103367","volume":"163","author":"CH Kim","year":"2021","unstructured":"Kim CH, Leitch HA. Iron overload-induced oxidative stress in myelodysplastic syndromes and its cellular sequelae. Crit Rev Oncol\/Hematol. 2021;163:103367.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"5\u20136","key":"4986_CR70","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/10408363.2010.550461","volume":"47","author":"MM Speeckaert","year":"2010","unstructured":"Speeckaert MM, Speeckaert R, Delanghe JR. Biological and clinical aspects of soluble transferrin receptor. Crit Rev Clin Lab Sci. 2010;47(5\u20136):213\u201328.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"1\u20132","key":"4986_CR71","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0009-8981(03)00005-6","volume":"329","author":"Y Beguin","year":"2003","unstructured":"Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta. 2003;329(1\u20132):9\u201322.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"4986_CR72","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1600-0609.2007.00863.x","volume":"79","author":"G Metzgeroth","year":"2007","unstructured":"Metzgeroth G, Ros\u00e9e PL, Kuhn C, Schultheis B, Dorn-Beineke A, Hehlmann R, et al. The soluble transferrin receptor in dysplastic erythropoiesis in myelodysplastic syndrome. Eur J Haematol. 2007;79(1):8\u201316.","journal-title":"Eur J Haematol"},{"issue":"8","key":"4986_CR73","doi-asserted-by":"publisher","first-page":"e23109","DOI":"10.1371\/journal.pone.0023109","volume":"6","author":"V Santini","year":"2011","unstructured":"Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS ONE. 2011;6(8):e23109.","journal-title":"PLoS ONE"},{"issue":"5","key":"4986_CR74","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1177\/10815589241246541","volume":"72","author":"J Li","year":"2024","unstructured":"Li J, Ma J, Zhang R, Zhai Y, Zhang W, Fu R. A new therapeutic perspective: Erastin inhibits tumor progression by driving ferroptosis in myelodysplastic syndromes. J Investig Med. 2024;72(5):414\u201324.","journal-title":"J Investig Med"},{"issue":"2","key":"4986_CR75","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.beha.2004.10.003","volume":"18","author":"ZI Cabantchik","year":"2005","unstructured":"Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18(2):277\u201387.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"4986_CR76","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/10245332.2016.1199178","volume":"22","author":"S Gu","year":"2017","unstructured":"Gu S, Xv Y, Fei C, Xiao C, Guo J, Zhao Y, et al. Labile plasma iron, more practical and more sensitive to iron overload in myelodysplastic syndromes. Hematology. 2017;22(1):9\u201315.","journal-title":"Hematology"},{"issue":"2","key":"4986_CR77","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.hoc.2010.02.003","volume":"24","author":"M Bartenstein","year":"2010","unstructured":"Bartenstein M, Deeg HJ. Hematopoietic stem cell transplantation for MDS. Hematology\/Oncology Clin. 2010;24(2):407\u201322.","journal-title":"Hematology\/Oncology Clin"},{"key":"4986_CR78","doi-asserted-by":"publisher","first-page":"650473","DOI":"10.3389\/fonc.2021.650473","volume":"11","author":"C Kordella","year":"2021","unstructured":"Kordella C, Lamprianidou E, Kotsianidis I. Mechanisms of action of hypomethylating agents: endogenous retroelements at the epicenter. Front Oncol. 2021;11:650473.","journal-title":"Front Oncol"},{"issue":"1","key":"4986_CR79","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/tme.12841","volume":"32","author":"S Kaka","year":"2022","unstructured":"Kaka S, Jahangirnia A, Beauregard N, Davis A, Tinmouth A, Chin-Yee N. Red blood cell transfusion in myelodysplastic syndromes: A systematic review. Transfus Med. 2022;32(1):3\u201323.","journal-title":"Transfus Med"},{"issue":"8","key":"4986_CR80","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1080\/21645515.2021.1898307","volume":"17","author":"K Linder","year":"2021","unstructured":"Linder K, Lulla P. Myelodysplastic syndrome and immunotherapy novel to next in-line treatments. Hum Vaccines Immunotherapeutics. 2021;17(8):2602\u201316.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"4986_CR81","unstructured":"Gounden V, Bhatt H, Jialal I. Renal Function Tests: StatPearls Publishing, Treasure Island (FL); 2021 2021."},{"issue":"5","key":"4986_CR82","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jtct.2020.11.007","volume":"27","author":"A Isidori","year":"2021","unstructured":"Isidori A, Loscocco F, Visani G, Chiarucci M, Musto P, Kubasch A-S, et al. Iron toxicity and chelation therapy in hematopoietic stem cell transplant. Transplantation Cell therapy. 2021;27(5):371\u20139.","journal-title":"Transplantation Cell therapy"},{"issue":"5","key":"4986_CR83","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.blre.2013.07.003","volume":"27","author":"AM Zeidan","year":"2013","unstructured":"Zeidan AM, Linhares Y, Gore SD. Current therapy of myelodysplastic syndromes. Blood Rev. 2013;27(5):243\u201359.","journal-title":"Blood Rev"},{"key":"4986_CR84","doi-asserted-by":"crossref","unstructured":"Belasen A, Navada S. Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure. J Sci Innov Med. 2020;3(3).","DOI":"10.29024\/jsim.62"},{"issue":"5","key":"4986_CR85","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1080\/10428194.2016.1228927","volume":"58","author":"B Ball","year":"2017","unstructured":"Ball B, Zeidan A, Gore SD, Prebet T. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. Leuk Lymphoma. 2017;58(5):1022\u201336.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"4986_CR86","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/2040620711435659","volume":"3","author":"VH Duong","year":"2012","unstructured":"Duong VH, Komrokji RS, List AF. Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. Therapeutic Adv Hematol. 2012;3(2):105\u201316.","journal-title":"Therapeutic Adv Hematol"},{"key":"4986_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.blre.2018.09.001","volume":"34","author":"AM Zeidan","year":"2019","unstructured":"Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1\u201315.","journal-title":"Blood Rev"},{"key":"4986_CR88","doi-asserted-by":"publisher","first-page":"100689","DOI":"10.1016\/j.blre.2020.100689","volume":"45","author":"E Scalzulli","year":"2021","unstructured":"Scalzulli E, Pepe S, Colafigli G, Breccia M. Therapeutic strategies in low and high-risk MDS: What does the future have to offer? Blood Rev. 2021;45:100689.","journal-title":"Blood Rev"},{"issue":"1","key":"4986_CR89","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.4081\/hr.2010.e1","volume":"2","author":"C Sugimori","year":"2010","unstructured":"Sugimori C, List AF, Epling-Burnette PK. Immune dysregulation in myelodysplastic syndrome. Hematol Rep. 2010;2(1):e1.","journal-title":"Hematol Rep"},{"issue":"1","key":"4986_CR90","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41392-023-01521-5","volume":"8","author":"L Tang","year":"2023","unstructured":"Tang L, Huang Z, Mei H, Hu Y. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct Target Therapy. 2023;8(1):306.","journal-title":"Signal Transduct Target Therapy"},{"issue":"9","key":"4986_CR91","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s11095-024-03761-8","volume":"41","author":"M Gandhi","year":"2024","unstructured":"Gandhi M, Sharma B, Nair S, Vaidya AD. Current insights into CAR T-cell-based therapies for myelodysplastic syndrome. Pharm Res. 2024;41(9):1757\u201373.","journal-title":"Pharm Res"},{"key":"4986_CR92","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.exphem.2019.05.002","volume":"74","author":"BM Stevens","year":"2019","unstructured":"Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, et al. CD123 CAR T cells for the treatment of myelodysplastic syndrome. Exp Hematol. 2019;74:52\u201363. e3.","journal-title":"Exp Hematol"},{"issue":"1","key":"4986_CR93","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cmet.2019.06.012","volume":"30","author":"BR Stockwell","year":"2019","unstructured":"Stockwell BR, Jiang X. A physiological function for ferroptosis in tumor suppression by the immune system. Cell Metabol. 2019;30(1):14\u20135.","journal-title":"Cell Metabol"},{"issue":"6","key":"4986_CR94","doi-asserted-by":"publisher","first-page":"e20210518","DOI":"10.1084\/jem.20210518","volume":"218","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Ferroptosis in infection, inflammation, and immunity. J Exp Med. 2021;218(6):e20210518.","journal-title":"J Exp Med"},{"issue":"2","key":"4986_CR95","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41556-020-0461-8","volume":"22","author":"H Lee","year":"2020","unstructured":"Lee H, Zandkarimi F, Zhang Y, Meena JK, Kim J, Zhuang L, et al. Energy-stress-mediated AMPK activation inhibits ferroptosis. Nat Cell Biol. 2020;22(2):225\u201334.","journal-title":"Nat Cell Biol"},{"issue":"7","key":"4986_CR96","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22(7):381\u201396.","journal-title":"Nat Rev Cancer"},{"key":"4986_CR97","doi-asserted-by":"publisher","first-page":"1561072","DOI":"10.3389\/fphar.2025.1561072","volume":"16","author":"Y Yang","year":"2025","unstructured":"Yang Y, Han J, Wei Y, Jin J, Feng W. Research progress on ferroptosis in Myelodysplastic syndromes. Front Pharmacol. 2025;16:1561072.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4986_CR98","first-page":"166","volume":"2008","author":"M Cazzola","year":"2008","unstructured":"Cazzola M, Della Porta MG, Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. ASH Educ Program Book. 2008;2008(1):166\u201375.","journal-title":"ASH Educ Program Book"},{"issue":"1","key":"4986_CR99","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1416","volume":"10","author":"SJ Dixon","year":"2014","unstructured":"Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10(1):9\u201317.","journal-title":"Nat Chem Biol"},{"issue":"7146","key":"4986_CR100","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nature05859","volume":"447","author":"N Yagoda","year":"2007","unstructured":"Yagoda N, Von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, et al. RAS\u2013RAF\u2013MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447(7146):865\u20139.","journal-title":"Nature"},{"issue":"6","key":"4986_CR101","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1002\/anie.201510031","volume":"55","author":"C Zhang","year":"2016","unstructured":"Zhang C, Bu W, Ni D, Zhang S, Li Q, Yao Z, et al. Synthesis of iron nanometallic glasses and their application in cancer therapy by a localized Fenton reaction. Angew Chem Int Ed. 2016;55(6):2101\u20136.","journal-title":"Angew Chem Int Ed"},{"issue":"1","key":"4986_CR102","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1):317\u201331.","journal-title":"Cell"},{"issue":"13","key":"4986_CR103","doi-asserted-by":"publisher","first-page":"6452","DOI":"10.3390\/ijms26136452","volume":"26","author":"J Lee","year":"2025","unstructured":"Lee J, Seo Y, Roh J-L. Emerging Therapeutic Strategies Targeting GPX4-Mediated Ferroptosis in Head and Neck Cancer. Int J Mol Sci. 2025;26(13):6452.","journal-title":"Int J Mol Sci"},{"key":"4986_CR104","doi-asserted-by":"crossref","unstructured":"Du L, Zhang Y, Luo J, He C, Lang J, Cao X. Epigenetic and post-translational regulatory networks of ferroptosis in the tumor immune microenvironment. Experimental Hematology & Oncology; 2026.","DOI":"10.1186\/s40164-025-00737-1"},{"key":"4986_CR105","doi-asserted-by":"crossref","unstructured":"Chen ZW, Shan JJ, Chen M, Wu Z, Zhao YM, Zhu HX et al. Targeting GPX4 to Induce Ferroptosis Overcomes Chemoresistance Mediated by the PAX8-AS1\/GPX4 Axis in Intrahepatic Cholangiocarcinoma. Adv Sci. 2025:e01042.","DOI":"10.1002\/advs.202501042"},{"issue":"5","key":"4986_CR106","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.chembiol.2019.01.008","volume":"26","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Tan H, Daniels JD, Zandkarimi F, Liu H, Brown LM, et al. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem biology. 2019;26(5):623\u201333. e9.","journal-title":"Cell Chem biology"},{"issue":"7","key":"4986_CR107","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41419-021-03998-w","volume":"12","author":"J Zheng","year":"2021","unstructured":"Zheng J, Sato M, Mishima E, Sato H, Proneth B, Conrad M. Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines. Cell Death Dis. 2021;12(7):698.","journal-title":"Cell Death Dis"},{"issue":"11","key":"4986_CR108","first-page":"6417","volume":"34","author":"E Lachaier","year":"2014","unstructured":"Lachaier E, Louandre C, Godin C, Saidak Z, Baert M, Diouf M, et al. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res. 2014;34(11):6417\u201322.","journal-title":"Anticancer Res"},{"key":"4986_CR109","doi-asserted-by":"crossref","unstructured":"Xu C, Sun S, Johnson T, Qi R, Zhang S, Zhang J et al. The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. Cell Rep. 2021;35(11).","DOI":"10.1016\/j.celrep.2021.109235"},{"issue":"1","key":"4986_CR110","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/cdd.2017.171","volume":"25","author":"AM Kaiser","year":"2018","unstructured":"Kaiser AM, Attardi LD. Deconstructing networks of p53-mediated tumor suppression in vivo. Cell Death Differ. 2018;25(1):93\u2013103.","journal-title":"Cell Death Differ"},{"issue":"2","key":"4986_CR111","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3324\/haematol.2020.259531","volume":"107","author":"R Birsen","year":"2021","unstructured":"Birsen R, Larrue C, Decroocq J, Johnson N, Guiraud N, Gotanegre M, et al. APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. Haematologica. 2021;107(2):403.","journal-title":"Haematologica"},{"issue":"37","key":"4986_CR112","doi-asserted-by":"publisher","first-page":"eabm9427","DOI":"10.1126\/sciadv.abm9427","volume":"8","author":"KM Fujihara","year":"2022","unstructured":"Fujihara KM, Zhang BZ, Jackson TD, Ogunkola MO, Nijagal B, Milne JV, et al. Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction. Sci Adv. 2022;8(37):eabm9427.","journal-title":"Sci Adv"},{"issue":"13","key":"4986_CR113","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1080\/10428194.2022.2116932","volume":"63","author":"Y Wei","year":"2022","unstructured":"Wei Y, Zheng H, Lockyer PP, Darbaniyan F, Li Z, Kanagal-Shamanna R, et al. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma. 2022;63(13):3154\u201364.","journal-title":"Leuk Lymphoma"},{"key":"4986_CR114","doi-asserted-by":"publisher","first-page":"122629","DOI":"10.1016\/j.lfs.2024.122629","volume":"346","author":"N Dhas","year":"2024","unstructured":"Dhas N, Kudarha R, Tiwari R, Tiwari G, Garg N, Kumar P, et al. Recent advancements in nanomaterial-mediated ferroptosis-induced cancer therapy: importance of molecular dynamics and novel strategies. Life Sci. 2024;346:122629.","journal-title":"Life Sci"},{"key":"4986_CR115","doi-asserted-by":"publisher","first-page":"1477938","DOI":"10.3389\/fphar.2024.1477938","volume":"15","author":"S Cao","year":"2024","unstructured":"Cao S, Wei Y, Yue Y, Wang D, Yang J, Xiong A, et al. Mapping the evolution and research landscape of ferroptosis-targeted nanomedicine: insights from a scientometric analysis. Front Pharmacol. 2024;15:1477938.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4986_CR116","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12951-024-02842-5","volume":"22","author":"S Han","year":"2024","unstructured":"Han S, Zou J, Xiao F, Xian J, Liu Z, Li M, et al. Nanobiotechnology boosts ferroptosis: opportunities and challenges. J Nanobiotechnol. 2024;22(1):606.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"4986_CR117","doi-asserted-by":"publisher","first-page":"2527752","DOI":"10.1080\/10717544.2025.2527752","volume":"32","author":"Y Xu","year":"2025","unstructured":"Xu Y, Zhang K, Ye Z, Huang Z, Chen R, Zhang Y, et al. Nanomedicine initiates ferroptosis for enhanced lung cancer therapy. Drug Delivery. 2025;32(1):2527752.","journal-title":"Drug Delivery"},{"issue":"1","key":"4986_CR118","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1186\/s12967-025-07107-9","volume":"23","author":"M Zhu","year":"2025","unstructured":"Zhu M, Zhao Y, Xu L, Sun M, Sun Y. Mn-Zn ferrite nanoparticles inducing ferroptosis to reverse the resistance in CML cells. J Translational Med. 2025;23(1):1071.","journal-title":"J Translational Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04986-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04986-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04986-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:15:47Z","timestamp":1783397747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04986-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":118,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4986"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04986-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"993"}}